Cell therapy to prevent lung disease in very premature babies
Part of Genetic & congenital, Infections, Lungs & breathing clinical trials.
This study tests whether a special cell therapy (MSC-EVs) given to extremely premature babies can help prevent a serious lung disease called bronchopulmonary dysplasia (BPD). The treatment is given while the baby is still on a breathing machine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is born extremely early, between 23 and 28 weeks of pregnancy.
- Your baby weighs between 500 grams and 1500 grams at birth.
- Your baby is on a breathing machine (ventilator) with extra oxygen between 3 and 10 days after birth.
- Your baby does not have serious heart or lung problems, severe infections, or a recent brain bleed.
- You can give permission for your baby to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether giving stem cells into a breathing tube is safe and may help prevent bronchopulmonary dysplasia (BPD), a serious lung condition in very premature infants. It focuses on babies soon after birth who already need breathing support and are at risk.
This trial tests if stem cells can help premature babies with severe lung disease (bronchopulmonary dysplasia). It is for very small, early-born babies who still need a breathing machine between 5 and 14 days after birth.
This trial tests if intravenous immunoglobulin (IVIG) can help prevent or treat bronchopulmonary dysplasia (BPD), a lung condition in premature babies. It is for very preterm infants born between 25 and 29 weeks who show early signs of BPD and are enrolled in the first day of life.
This trial tests whether giving intravenous immunoglobulin (IVIG) early after birth can help prevent or treat a serious lung condition called bronchopulmonary dysplasia (BPD) in babies born at 28 weeks or earlier. It may help reduce the need for breathing support and oxygen.
This trial tests a medicine called zelpultide alfa in very premature babies who are at high risk of developing bronchopulmonary dysplasia (BPD), a chronic lung disease. The goal is to see if it can help prevent or lessen lung problems compared to standard care alone.
This study tests a new way of setting the ventilator for preterm babies born before 34 weeks who are still on a breathing machine. It aims to improve lung healing and heart function by finding the best pressure settings. The results could help your baby breathe more comfortably.
Hear when a new Bronchopulmonary Dysplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.